Supernus Pharmaceuticals | SUPN - Interest Expense On Debt


Supernus Pharmaceuticals reported $910K in Interest Expense on Debt for its fiscal quarter ending in June of 2023.





Interest Expense On Debt Change Date
Abbott USD 68M 26M Mar/2026
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Aurora Cannabis CAD 2.11M 116K Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Canopy Growth CAD 7.34M 1.46M Dec/2025
Cara Therapeutics -89.64M 128.67M Dec/2025
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Eisai JPY 1.55B 117M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Pfizer USD 671M 40M Mar/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
United Therapeutics USD 3.1M 100K Dec/2025
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025